×
About 2,030 results

ALLMedicine™ Burkitt Lymphoma Center

Research & Reviews  757 results

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocate...
https://doi.org/10.1182/bloodadvances.2022007475
Blood Advances; Ferreri AJM, Angelillo P et. al.

May 18th, 2022 - Patients with aggressive B-cell lymphoma and MYC rearrangement at FISH exhibit poor outcome after R-CHOP. In the last decade, 68 patients with Burkitt lymphoma (BL; n=46) or high-grade B-cell lymphoma (single, double or triple hit; HGBCL; n=22) we...

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID seems t...
https://doi.org/10.1002/eji.202249820
European Journal of Immunology; Summerauer AM, Jäggi V et. al.

May 4th, 2022 - Endemic Burkitt lymphoma (eBL) is characterized by an oncogenic IGH/c-MYC translocation and Epstein-Barr virus (EBV) positivity, and is epidemiologically linked to Plasmodium falciparum malaria. Both EBV and malaria are thought to contribute to eB...

Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic...
https://doi.org/10.3324/haematol.2021.280557
Haematologica Bomken S, Enshaei A et. al.

Apr 30th, 2022 - Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukaemia and use of unproven indi...

see more →

Guidelines  2 results

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  14 results

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
https://clinicaltrials.gov/ct2/show/NCT03620578

Mar 24th, 2022 - The dismal prognosis of DH-DLBCL patients following standard therapy with R-CHOP (overall survival at 2 years 35% for MYC+ vs 61% for MYC- patients) justifies upfront new treatment approaches. Attempts have been made to improve prognosis of DH-DLB...

Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment
https://clinicaltrials.gov/ct2/show/NCT03677128

Mar 22nd, 2022 - Each year, approximately 220,000 children globally are newly diagnosed with cancer. Over 85% of these new diagnoses are made in low- and middle-income countries (LMICs). Survival rates in LMICs are 5-25% compared to 80% in high-income countries (H...

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
https://clinicaltrials.gov/ct2/show/NCT03864419

Mar 10th, 2022 - OUTLINE: Open-label Phase I study characterizing the safety, tolerability, and activity of subcutaneous rituximab hyaluronidase (sqR) alone (KSHV-MCD), or combined with local standard of care chemotherapy (BL or DLBCL), in 2 age-based cohorts of p...

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving ...
https://clinicaltrials.gov/ct2/show/NCT05206357

Jan 25th, 2022 - The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of rela...

see more →

News  38 results

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

NCCN Guidelines Set New Pace for Pediatric ALL
https://www.onclive.com/view/nccn-guidelines-set-new-pace-for-pediatric-all

Jan 3rd, 2022 - Patrick Brown, MD With the recent publication of an inaugural set of guidelines for treatment of pediatric acute lymphoblastic leukemia (ALL), the National Comprehensive Cancer Network (NCCN) seeks to introduce standards to a branch of care long ...

FDA Approves Rituximab for Multiple Pediatric Cancers
https://www.medscape.com/viewarticle/964124

Dec 3rd, 2021 - The US Food and Drug Administration yesterday approved rituximab (Rituxan) in combination with chemotherapy for pediatric patients (age 6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (...

Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt Lymphoma
https://www.onclive.com/view/dr-noy-on-the-rationale-to-evaluate-devimistat-in-burkitt-lymphoma

Oct 6th, 2021 - Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either relapsed/refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma. Patients...

Polatuzumab Vedotin Plus R-CHP Significantly Improves PFS Over R-CHOP in DLBCL
https://www.onclive.com/view/polatuzumab-vedotin-plus-r-chp-significantly-improves-pfs-over-r-chop-in-dlbcl

Aug 10th, 2021 - Polatuzumab vedotin-piiq (Polivy) in combination with rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs ri...

see more →